Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11135656 | 0.86 | CYP1A2 (0.48) | PPARGPPARACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL9749675 | 0.85 | CYP1A2 (0.48) | CYP1A2CYP2C19FAAH | |
| SCHEMBL9749115 | 0.81 | PPARG (0.41) | PPARGPPARACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL11460264 | 0.76 | L3MBTL1 (0.48) | — | |
| SCHEMBL9365846 | 0.75 | ALDH1A1 (0.44) | CYP1A2CYP2C19ALDH1A1MAPTHPGD | |
| SCHEMBL9366093 | 0.75 | ALDH1A1 (0.44) | CYP1A2CYP2C19ALDH1A1MAPTHPGD | |
| SCHEMBL11135839 | 0.74 | LMNA (0.48) | PPARGPPARACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL9361930 | 0.74 | ALDH1A1 (0.43) | CYP1A2CYP2C19ALDH1A1MAPTHPGD | |
| SCHEMBL28309323 | 0.72 | ALDH1A1 (0.57) | CYP1A2CYP2C19ALDH1A1MAPTHPGD | |
| SCHEMBL9362087 | 0.72 | CYP1A2 (0.43) | CYP1A2CYP2C19ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0493404-A4 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | — | 1992-08-12 | — | — | EP | claimed |
| EP-0493404-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | claimed |
| US-5091379-A | Dermatitis, side effect reduction | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-25 | — | — | US | claimed |
| WO-1991003227-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | claimed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | claimed |
| EP-0493404-A4 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | — | 1992-08-12 | — | — | EP | disclosed |
| EP-0493404-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5091379-A | Dermatitis, side effect reduction | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-25 | — | — | US | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| WO-1991003227-A1 | TOPICAL ANTIINFLAMMATORY COMPOSITIONS WITH MINIMAL SYSTEMIC ABSORPTION | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-03-21 | — | — | WO | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |